Loading...
Loading chart...



The current price of KRON is 0 USD — it has increased 0 % in the last trading day.
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Its product candidates include KB-9558 and KB-7898. KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN, is in preclinical development for the treatment of multiple myeloma and human papillomavirus (HPV)-driven tumors. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. KB-7898 is a p300 KAT inhibitor for the treatment of Sjogren’s disease, a chronic autoimmune disease that is characterized by the production of autoantibodies, chronic inflammation and lymphocytic infiltration of the exocrine glands that lead to uncomfortable dryness symptoms, known as sicca.
Wall Street analysts forecast KRON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRON is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Kronos Bio Inc revenue for the last quarter amounts to 2.00M USD, decreased -26.03 % YoY.
Kronos Bio Inc. EPS for the last quarter amounts to -0.14 USD, decreased -72.00 % YoY.
Kronos Bio Inc (KRON) has 10 emplpoyees as of January 31 2026.
Today KRON has the market capitalization of 72.00M USD.